Factors associated with isoniazid preventive treatment interruption and completion among PLHIV in Gombe Hospital, Uganda, 2017–2019. (May 2023)

• Record Type: Journal Article
• Authors: Ssendikwanawa, Emmanuel; Juniour Nsubuga, Edirisa; Lee, Seungwon; Frances Zalwango, Jane; Joan Bayowa, Rokani; Judith Ssemasaazi, Amuntuhaire; Ronald Muganga, Kivumbi; Adolphus, Cherop; Akunzirwe, Rebecca; Nante Wangi, Rachel; Ronald Kasoma, Mutebi; Kalyango, Joan N.; Karamagi, Charles; Sekaggya-Wiltshire, Christine
• Is Part Of: Journal of clinical tuberculosis and other mycobacterial diseases. Volume 31(2023)
• Publication Date: 2023-05
• Subjects: ART Antiretroviral Therapy -- IDI In Depth Interview -- KII Key Informant Interview -- PLHIV People Living with Human Immunodeficiency Virus -- IPT Isoniazid Preventive Treatment; Tuberculosis -- Isoniazid preventive treatment -- Isoniazid preventive treatment interruption -- Isoniazid preventive treatment completion -- Persons living with HIV -- Uganda; Tuberculosis -- Periodicals; Mycobacterial diseases -- Periodicals; 616.995
• DOI: 10.1016/j.jctube.2023.100349
• Languages: English
• ISSNs: 2405-5794

Abstract

Abstract: Background: Tuberculosis (TB) is the leading cause of death in persons living with HIV (PLHIV). PLHIV carry a disproportionate burden of TB infection with risks 20–37 times greater than HIV-negative populations. While isoniazid preventive treatment (IPT) is regarded as a crucial component of HIV care to prevent active TB, the uptake among PLHIV remains very poor. Studies on the factors associated with IPT interruption and completion among PLHIV in Uganda are scarce. Thus, in Gombe Hospital in Uganda, this study assessed the factors associated with IPT interruption and completion among PLHIV. Methods: This was a hospital-based cross-sectional study that used both quantitative and qualitative methods of data collection from January 3rd, 2020 to February 28th, 2020. We reviewed the medical records of 686 PLHIV who received IPT at Gombe Hospital from January 1st, 2017 to December 31st, 2019. Binary logistic and modified Poisson regression were used to analyze factors associated with IPT completion and interruption. We conducted 7 key informant interviews and 14 in-depth interviews. Results: Second-line antiretroviral therapy (AOR = 46, p < 0.001) and age ≥ 45 years (AOR = 0.2, p = 0.040) were significantly associated with IPT interruption, while attending routine ART counseling sessions (APR = 1.5, p < 0.001) and prescription for ≥ 2 months at the start of IPT (APR = 1.1, p = 0.010) were associated with IPT completion. Barriers to IPT completion included pill burden, forgetfulness, poor integration of IPT in HIV healthcare services, and lack of awareness of IPT, while facilitators were easy accessibility of IPT and support from implementing partners. Conclusions: Side effects and pill burden were the major barriers to the long-term completion of IPT. Supplying ≥ 2 months IPT drugs, using IPT drugs with fewer side effects, and counseling during IPT could improve IPT completion and reduce IPT interruption.